Transplant Diagnostics Global Market Report 2024

The transplant diagnostics market size has grown rapidly in recent years. It will grow from $1.82 billion in 2023 to $2.01 billion in 2024 at a compound annual growth rate (CAGR) of 10.7%. The growth observed in the historical period can be ascribed to the advancement of HLA typing, the expansion of organ transplantations, progress in immunosuppressive therapy, the introduction of cross-matching techniques, and the standardization of regulatory measures.

The transplant diagnostics market size is expected to see strong growth in the next few years. It will grow to $2.57 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%. The anticipated growth in the forecast period can be credited to patient-centric approaches, regulatory adaptations, an increase in living donor transplants, personalized transplant medicine, and the overall growth in transplant procedures. Major trends expected in the forecast period include education and awareness programs, strategies for market expansion, the evolution of regulatory guidelines, optimization of immunosuppressive therapy, and the development of biomarkers.

The increasing incidence of acute diseases is contributing to a rise in organ failure rates, leading to a heightened demand for transplant procedures and subsequently propelling the transplant diagnostics market. Organ transplantations are intricate processes, and the success of such procedures hinges on the compatibility of the donor's organ with the recipient's body system. To assess the potential success of organ transplants, diagnostic tests are conducted. According to the United Network for Organ Sharing, a non-profit organization overseeing organ transplantation in the US, the year 2021 witnessed a record-setting number of organ transplants. Notably, 24,669 kidney transplants, 9,236 liver transplants, and 3,817 heart transplant procedures were conducted in 2021. This surge in demand for diagnostic tests is a significant driver for the transplant diagnostics market.

The increasing prevalence of organ transplants is anticipated to fuel the transplant diagnostics market's growth. Organ transplantation, involving the removal of organs, tissues, or cells from a donor to be transplanted into a recipient, plays a critical role in improving outcomes and compatibility assessment. Transplant diagnostics are essential for pre-transplant donor eligibility screening, identification of post-transplant complications, and monitoring the effectiveness of antimicrobial agents. For example, as of January 2022, the United Network for Organ Sharing reported that the number of organ transplants in the United States reached 41,354 in 2021, marking a 5.9% increase from the previous year and surpassing the 40,000 milestone for the first time. Consequently, the growing number of organ transplants is a key driver for the transplant diagnostics market.

The substantial gap between organ donation and the demand for organ transplantation poses a challenge to the transplant diagnostics market's growth. The insufficient number of organ donors falls significantly short of meeting the increasing demand for organ transplants. As of 2021, the Health Resources and Services Administration reported that 106,090 people were on the waiting list for organ donations. This widening gap between organ supply and demand contributes to a deficit of organ donors, limiting the requirement for transplant diagnostic tests and devices and consequently impeding market growth.

Prominent companies in the transplant diagnostics market are strategically introducing advanced services to enhance their market profitability. Advanced transplant diagnostic services entail the utilization of innovative diagnostic tools and technologies to enhance the precision and efficiency of pre-transplant and post-transplant testing procedures. For example, in March 2023, Quest Diagnostics, a US-based medical laboratory company, unveiled Quest Advanced Specialized Transplant Services, an extensive array of cutting-edge diagnostics and support services designed to enhance access to laboratory tests for solid organ, human cell, and tissue transplants. This comprehensive offering includes over 170 specialized transplant and infectious disease tests, longitudinal trend analysis of test results integrated into the physician's electronic medical record (EMR), and 24/7 support services, including medical consultation to ensure appropriate test selection and result interpretation impacting patient care. The new services expand upon Quest's previous transplant testing offerings with added capabilities, including patient-customized information packets and expedited testing for patients visiting Quest's 2,100 patient service centers, with some test results obtainable within 8–24 hours.

Companies are increasingly adopting Next Generation Sequencing (NGS) for donor-recipient matching tests. NGS technology facilitates the sequencing of an entire human genome, enabling the matching of genes between donors and recipients to determine the suitability for organ transplantation. Virtually all current transplant diagnostic tests and devices leverage NGS technology to inform decisions related to organ transplantation. Castle Biosciences, for instance, introduced the Decision Dx-CMSeq Test, utilizing NGS (Next Generation Sequencing) to identify somatic mutations in genes.

In August 2022, Eurobio Scientific, a biotechnology company based in France, completed the acquisition of GenDx for $134.3 million (€135 million). This strategic move is anticipated to bolster Eurobio's research efforts in the field of transplantation. GenDx is a molecular diagnostics startup headquartered in the Netherlands.

Major companies operating in the transplant diagnostics market report are F. Hoffmann La-Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Becton-Dickinson and Company, Hologic Inc., Illumina Inc., BioMerieus S.A, Biomérieux SA, Grafton Companies, Bio-rad Laboratories Inc., Sigma-Aldrich Corporation, Qiagen N.V., Immucor Transplant Diagnostics Inc., Immucor Inc., Luminex Corporation, Affymetrix Inc., CareDx Company, One Lambda Inc., Eurobio Scientific Group, Gendx BV, Olerup SSp AB, Genome Diagnostics B.V., Transplant Genomics Inc., Omixon Ltd., BAG Healthcare GmbH, Histogenetics Inc., Linkage Biosciences lnc., Gendrive PLC, BioGenuix, Pure Transplant Solutions. North America was the largest region in the transplant diagnostics market in 2023. Western Europe was the second largest region in the transplant diagnostics market report. The regions covered in the transplant diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The primary categories within the transplant diagnostics market include reagents and consumables, instruments, and software and services. Transplant diagnostics instruments are specifically designed products aimed at enhancing the speed and quality of transplant diagnostics. Employing non-molecular assay and molecular assay technologies, transplant diagnostics cover various organs such as kidneys, liver, heart, lungs, and pancreas. The transplant types involved are solid organ and stem cells, with end-users including hospitals and transplant centers, research laboratories and transplant centers, as well as commercial service providers.

The transplant diagnostics market research report is one of a series of new reports that provides transplant diagnostics market statistics, including transplant diagnostics industry global market size, regional shares, competitors with a transplant diagnostics market share, detailed transplant diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the transplant diagnostics industry. This transplant diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The countries covered in the transplant diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The transplant diagnostics market includes revenues earned by entities by PCR-based molecular assays, sequencing-based molecular assays, and non-molecular assay technologies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.